Béa Fertility
Company Intelligence Report
Comprehensive analysis of company details, tech stack, recruitment, and market position
Company Snapshot
Location
London, United Kingdom
Registered Name
StepOne Fertility Ltd
Website & Social
Company Bio
Béa Fertility is a VC-backed scale-up that offers natural and non-invasive fertility treatment programmes to couples. The company has developed an innovative at-home fertility treatment kit, making fertility care more accessible and affordable. Their hormone-free, intracervical insemination (ICI) applicator brings IVF-level fertility treatment into the home.
Béa aims to bridge the gap between intercourse and IVF, providing clinical-grade fertility care at a fraction of the cost. The company reported a 39.28% pregnancy rate over three treatment cycles in their initial user group. The Béa Treatment is FDA-cleared, HSA/FSA eligible, and designed to be used entirely from home with ongoing support from fertility clinicians.
The company launched its comprehensive Béa Fertility Treatment in 2024, combining 3 cycles of ICI treatment with unlimited access to a dedicated Clinical Coach, digital support, and emotional guidance — reflecting customer demand for more human-centered care.
Market & Domain
Market Category
Hospitals and Health Care
Market Domain
B2C
Target Region
UK (initially), expanding to US
Official Records
Company Details
Company Name
STEPONE FERTILITY LTD
Company Number
12539481
Company Type
Private Limited Company
Status
Active
Date of Incorporation
30 March 2020
Next Accounts Due
31 December 2025
Nature of Business (SIC)
71129 - Other engineering activities
86900 - Other human health activities
Full Address
St. Johns Court, 144–146 St. John's Hill, London, England, SW11 1SN
Official Links
Persons with Significant Control (PSCs)
Ms Tess Isabelle Cosad
Nationality: French, American
Born: April 1991
Natures of Control
- Ownership of shares (25% to 50%)
- Voting rights (25% to 50%)
- Right to appoint and remove directors
Mr David Gerard O'Rourke
Nationality: Irish
Born: July 1985
Natures of Control
- Ownership of shares (25% to 50%)
- Voting rights (25% to 50%)
- Right to appoint and remove directors
Tech Stack
Development & Programming
Hosting & Infrastructure
Analytics & Tracking
Marketing Tools
Recruitment Data
Current Job Listings
| Title | Location | Post Date |
|---|---|---|
| Senior Fertility Nurse | London, UK | 5 days ago |
| Clinical Coach | Remote, UK | 12 days ago |
| Content Writer (Fertility) | Remote | 20 days ago |
Company Benefits
Health & Wellness
- Private medical insurance
- Fertility treatment support
- Mental health support
Financial
- Competitive salary
- Equity options
Development
- Professional development budget
- Conference attendance
Work-Life Balance
- Remote work options
- Generous holiday allowance
- Enhanced parental leave
Customer Feedback
Customer Reviews Summary
Total Reviews
5
Average Rating
5.0
Most Recent
18 July 2025
"Tried Bea Fertility after trying to conceive placed a lot of stress on both me and my husband, especially after a previous miscarriage. The applicator was really easy to use and we are extremely lucky that it worked first time for us... I am now 14 weeks pregnant."
"Great customer service. We purchased the 3 cycle package. Had an initial virtual consultation with Sandy who answered all our questions and reassured us. On the second use, one of the devices was faulty and the team were prompt in their reply and sent us a replacement within a few days."
"We got pregnant our first try using Bea! I can’t thank and recommend Bea fertility enough! We got pregnant our first time using this after ttc for almost a year. Took the pressure and stress out of the whole thing..."
"Everything you need to know. Very easy to find out everything you need to before buying any treatments... Although we were unsuccessful with the treatments, I'm glad we had this option available to us to help us in our fertility journey."
"We wanted to give Béa a chance before IVF. Firstly, it's a lot cheaper than IVF and secondly a lot less invasive... After attending a few zoom seminars run by Tess and Sandy, I knew it was a treatment that I wanted to try."
Funding & News Signals
Latest News & Press
Pioneer Life Sciences Fund Invests In First Of Its Kind At-Home...
22.11.2023 — Pioneer Group today announced an investment in Béa Fertility to further expand the company's first of its kind at-home fertility treatment programme.
Read moreWhy we invested: Bea Fertility - 7percent Ventures
10.10.2024 — Oct 10, 2024 - Bea Fertility has developed a hormone-free, intracervical insemination (ICI) applicator, which takes IVF-level fertility...
Read moreBéa in the Press
"On the treatment side is burgeoning fertility-as-a-service startup Béa Fertility. Based in the UK, the startup plans to offer at-home fertility treatment as ..."
Read moreFunding Signals
Latest Funding Round - Convertible Note
Bea Fertility closed its last funding round on Aug 31, 2024 from a Convertible Note round. The company has raised funds over 5 rounds.
Source: CrunchbaseLead Investor - Pioneer Group
Pioneer Group is the lead investor in Béa Fertility's latest funding round held on Nov 22, 2023. Béa Fertility has a total of 25 investors.
Source: TracxnPrevious Funding Round - Venture
A previous Venture Round was held on July 31, 2023, with investors including Octopus Ventures.
Source: CrunchbaseCompany Health & Strategic Insights
- Financial Strength: StepOne Fertility Ltd demonstrates a stable financial position with £409,479 in net assets as of 31 March 2024, primarily driven by substantial share premium reserves (£3,863,362) offset by accumulated losses (£3,510,619). Current assets (£462,517) significantly exceed current liabilities (£141,597), ensuring strong liquidity.
- Operational Efficiency: The company maintains healthy cash reserves (£350,079), supporting operational flexibility. Key metrics indicate solid asset management, with tangible assets (£71,372) and intangible assets (£17,187) reflecting moderate investment in infrastructure and intellectual property.
- Market Position: Béa Fertility is a VC-backed scale-up offering natural and non-invasive fertility treatment programmes, bridging the gap between intercourse and IVF with clinical-grade fertility care at a fraction of the cost.
- Innovation & Technology: The company has developed an innovative at-home fertility treatment kit with a hormone-free, intracervical insemination (ICI) applicator that brings IVF-level fertility treatment into the home, reporting a 39.28% pregnancy rate over three treatment cycles.
- Compliance & Governance: The company's compliance with UK GAAP and the Companies Act 2006 is evident, though its exemption from audit under section 477 may limit external assurance. Revenue recognition policies are robust with clear criteria for goods and services.
- 🔑 Outlook: The company exhibits financial stability but should address accumulated losses and enhance transparency in profitability reporting to strengthen stakeholder confidence. Strategic focus on revenue growth and cost management is recommended for sustained success in the competitive fertility care market.